Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Home-Based Transitional Cardiac Rehabilitation Trial With a Partially Randomized Patient Preference Design

12. listopadu 2026 aktualizováno: Yu-Shan Lin, Cheng-Hsin General Hospital

A Confirmatory Non-Inferiority Trial of Home-Based Transitional Cardiac Rehabilitation, With a Partially Randomized Patient Preference (PRPP) Design, Informed by Pilot Data

This is a prospective, single-center, non-inferiority trial comparing a hospital-to-home transitional cardiac rehabilitation model with standard hospital-based cardiac rehabilitation in low-risk patients after cardiac surgery in Taiwan. Because patients' post-discharge scheduling constraints and treatment preferences make full randomization difficult to sustain in practice, the trial uses a Partially Randomized Patient Preference (PRPP) design: patients without a strong preference are randomized 1:1 to the two programs and form the randomized core cohort used for the primary confirmatory analysis, while patients with a clear, pre-specified preference are assigned accordingly and followed descriptively as a preference cohort. The primary hypothesis is that the hospital-to-home model is non-inferior to hospital-based rehabilitation in improving peak oxygen uptake (Peak VO2) after 8 weeks. A pre-specified key secondary hypothesis, based on an exploratory finding from the investigators' completed pilot study, is that the hospital-to-home model results in significantly lower 6-month outpatient medical costs. The trial does not include a no-treatment control arm; assay sensitivity is instead supported by the extensive existing evidence base for cardiac rehabilitation versus no treatment and for home-based versus center-based cardiac rehabilitation equivalence, following the constancy assumption described in ICH E10.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Rationale: A completed single-center pilot study (Cheng Hsin General Hospital institutional research grant, FY112) enrolled 30 patients (15 per arm, 4 withdrawals) and found a directional, exploratory signal of non-inferiority for the hospital-to-home model on Peak VO2, and a significant reduction in 6-month outpatient medical costs favoring the hospital-to-home arm. However, the pilot's original sample size was calculated using a two-tailed paired-sample t-test, which is not the correct method for a parallel-group non-inferiority design, so its non-inferiority conclusion was exploratory only. This confirmatory trial re-estimates the required sample size using the pilot's observed variance (ANCOVA-adjusted residual SD = 2.71 ml/min/kg) and the correct non-inferiority formula, and adopts a Partially Randomized Patient Preference (PRPP) design to address the real-world constraint that many post-discharge patients have strong scheduling or logistical preferences between an in-hospital and a home-based program.

Design: Prospective, parallel-group, non-inferiority trial with PRPP allocation. Patients without a strong preference (operationally defined as absence of a specific, identifiable scheduling, transportation, or technology-related constraint) are randomized 1:1 in permuted blocks to the hospital-to-home transitional model or hospital-based cardiac rehabilitation, forming the randomized core cohort (planned n=29 per arm, 58 total) that constitutes the intention-to-treat population for the primary confirmatory non-inferiority analysis. Patients with a clear, investigator-confirmed preference are assigned to their preferred program and followed as a preference cohort (planned n≈40) analyzed descriptively; their baseline characteristics are compared with the randomized core cohort to characterize potential selection effects, but they do not contribute to the primary confirmatory hypothesis test. Assuming approximately 60% of screened patients accept randomization (a planning assumption to be re-examined at the interim analysis), the overall enrollment target is 98 participants.

No-treatment control arm: The trial does not include a usual-care/no-rehabilitation control arm. The investigators considered a three-arm design to formally establish assay sensitivity but did not adopt it because (a) the effect of cardiac rehabilitation versus no treatment is already well established by a large existing evidence base, including the Cochrane meta-analyses cited in the 2026 ESC Guidelines on Cardiac Rehabilitation (85 RCTs / 23,430 patients in coronary artery disease; 60 RCTs / 8,728 patients in heart failure); (b) the equivalence of home-based and center-based cardiac rehabilitation has similarly been established at the meta-analytic level by the 2023 Cochrane review (24 RCTs, 3,046 patients); (c) adding a no-treatment arm would raise the enrollment target from 58 to approximately 134 in the randomized core cohort, which is not feasible for a single center; and (d) published hybrid cardiac rehabilitation non-inferiority/equivalence trials (iATTEND, HYCARET, and a French single-center trial) have similarly used two active comparator arms without a no-treatment control. This design relies on the ICH E10 constancy assumption rather than re-establishing assay sensitivity with concurrent trial data.

Outcome hierarchy: Given the number of secondary endpoints assessed in the pilot without multiplicity correction, this trial pre-specifies a hierarchical (fixed-sequence) gatekeeping procedure to control the family-wise type I error rate: Gate 1 tests the primary non-inferiority hypothesis on Peak VO2; Gate 2, tested only if Gate 1 is met, formally tests the pre-specified key secondary hypothesis on 6-month outpatient medical cost; Gate 3 outcomes (quality of life/QALY, medication adherence, secondary CPET indices, pulmonary function) are analyzed and reported descriptively as pre-specified but exploratory, without formal multiplicity control, and are entered under Other Pre-specified Outcome Measures below rather than Secondary Outcome Measures.

Missing data: Primary and secondary efficacy outcomes with missing values will be handled by multiple imputation (MICE, ≥20 imputations, pooled per Rubin's rules), with complete-case analysis as a sensitivity analysis. An interim analysis is planned at 50% enrollment for safety monitoring by an independent Data Safety Monitoring Board (DSMB); no interim efficacy testing is performed, so no alpha-spending adjustment is required. The interim analysis will also re-examine the actual randomization-acceptance rate against the 60% planning assumption and adjust the recruitment period or target if needed.

Typ studie

Intervenční

Zápis (Odhadovaný)

151

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: SHENG-CHI Lo, BS. PT.
  • Telefonní číslo: +886-02-28264400 EXT 3459
  • E-mail: fy10940619@gmail.com

Studijní záloha kontaktů

  • Jméno: Yu-Shan Lin, PT, MSc, CRFC
  • Telefonní číslo: +886-02-28264400 EXT 3459
  • E-mail: itsyushanlin@gmail.com

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

20 let až 75 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria

  • Post-cardiac-surgery patients at the study hospital
  • Age 20-75 years
  • Low cardiovascular risk (AHA 2013 exercise training risk stratification, Class B), clinically stable
  • Able to self-monitor exercise intensity

Exclusion Criteria

  • High risk of sudden cardiac death
  • Sustained atrial fibrillation or non-sustained ventricular tachycardia within the preceding 6 months
  • Implanted cardioverter-defibrillator (ICD)
  • Unable to independently operate the communication/exercise software or devices required for the home-based program
  • Declines to undergo study testing

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Singl

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Hybrid cardiac rehabilitation (Experimental)

Description:Weeks 1-2: 4 supervised hospital sessions (twice weekly). End of week 2: risk reassessment (AACVPR algorithm; patients with high-risk features do not transition to home) and teaching of home resistance exercise. Weeks 3-8: home aerobic exercise at least 3 times per week and elastic-band resistance exercise at least 2 times per week; remote 30-second ECG at rest daily and after each exercise session; exercise log; weekly telephone call; two standardized text messages per week; return visit at week 4. Participants choose this arm.

Hybrid cardiac rehabilitation (hospital-to-home transition):as in Arm 1; aerobic intensity is based on the anaerobic-threshold heart rate from baseline CPET when available, otherwise moderate intensity (RPE 12-13); resistance exercise uses elastic bands (4-8 exercises, RPE 11-13) with sternal precautions; intensity at home does not exceed the hospital sessions; upper-limb movements at home are added only after individual confirmation by the therapist.

Aktivní komparátor: Standard center-based cardiac rehabilitation (Active Comparator)

Description:Two supervised hospital sessions per week for 8 weeks (16 sessions), plus weekly verbal encouragement to exercise on their own and a home exercise log. Exercise prescription follows the hospital routine and is made in the same way as in the hybrid arm. Participants choose this arm.

Standard center-based cardiac rehabilitation:as in Arm 2.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing
Časové okno: Baseline (Week 0) and Week 8

Description:VO2peak (mL/kg/min) is the highest 30-second average oxygen uptake during a symptom-limited bicycle ramp cardiopulmonary exercise test with breath-by-breath gas analysis. Change = week 8 value minus week 0 value. Non-inferiority margin: 1.5 mL/kg/min.

Baseline (Week 0) and Week 8

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing at 6 Months After Week 8
Časové okno: 6 months after week 8

Description:Key secondary outcome. VO2peak (mL/kg/min) measured as for the primary outcome. Tested in a fixed sequence only if non-inferiority is shown for the primary outcome.

6 months after week 8
Number of Attended Supervised Exercise Sessions, From Hospital Attendance Records
Časové okno: Weeks 1-8.

Description:Count of supervised hospital sessions attended per participant (prescribed: 4 in the hybrid arm, 16 in the standard arm).

Weeks 1-8.
Number of Home Exercise Sessions per Week, Recorded in the Home Exercise Log
Časové okno: Weeks 1-8.

Description:Mean number of self-reported home exercise sessions per week (aerobic and resistance), from the participant's home exercise log.

Weeks 1-8.
Number of Participants Who Attend at Least 80% of Prescribed Supervised Sessions, From Hospital Attendance Records
Časové okno: Week 8.

Description:Participants attending at least 80% of the supervised sessions prescribed for their arm.

Week 8.
Health Utility Measured by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Index Score Using the Taiwan Value Set
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Description:The EQ-5D-5L describes health in 5 dimensions with 5 levels each; responses are converted to an index score with the Taiwan value set (Lin et al., PLoS One 2018). Index range -1.0259 to 1; 1 = full health; higher scores indicate better health.

Baseline (week 0), week 8, and 6 months after week 8
Self-Rated Health Measured by the EuroQol Visual Analogue Scale (EQ VAS)
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Description:EQ VAS ranges from 0 (worst imaginable health) to 100 (best imaginable health); higher scores indicate better health.

Baseline (week 0), week 8, and 6 months after week 8
Six-Minute Walk Distance Measured by the 6-Minute Walk Test
Časové okno: Baseline (week 0) and week 8

Description:Distance walked in 6 minutes (meters).

Baseline (week 0) and week 8
Patient Satisfaction Measured by the Client Satisfaction Questionnaire-8 (CSQ-8) Total Score
Časové okno: Week 8 and 6 months after week 8

Description:8 items each scored 1 to 4; total score ranges from 8 to 32; higher scores indicate greater satisfaction.

Week 8 and 6 months after week 8

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of Outpatient Visits, Excluding Cardiac Rehabilitation Sessions, From Hospital Records and National Health Insurance Data
Časové okno: From week 8 through 6 months after week 8

Count of outpatient visits per participant; cardiac rehabilitation sessions are excluded.

From week 8 through 6 months after week 8
Number of Emergency Department Visits, From Hospital Records and National Health Insurance Data
Časové okno: From week 8 through 6 months after week 8

Count of emergency department visits per participant.

From week 8 through 6 months after week 8
Number of Hospital Admissions, From Hospital Records and National Health Insurance Data
Časové okno: From week 8 through 6 months after week 8

Count of hospital admissions per participant.

From week 8 through 6 months after week 8
Total Length of Hospital Stay, From Hospital Records and National Health Insurance Data
Časové okno: From week 8 through 6 months after week 8

Total inpatient days per participant.

From week 8 through 6 months after week 8
Outpatient and Emergency Department Medical Expenditure, Excluding Cardiac Rehabilitation-Related Charges
Časové okno: From week 8 through 6 months after week 8

Total outpatient and emergency department medical expenditure per participant in New Taiwan Dollars (NTD), from hospital billing records and National Health Insurance data.

From week 8 through 6 months after week 8
Inpatient Medical Expenditure
Časové okno: From week 8 through 6 months after week 8

Total inpatient medical expenditure per participant in NTD, from hospital billing records and National Health Insurance data.

From week 8 through 6 months after week 8
Participant Time Spent on the Rehabilitation Program, Measured by a Study-Specific Time-Cost Questionnaire
Časové okno: Weeks 1-8

Total hours spent on travel to and from the hospital and on rehabilitation sessions (supervised and home-based) per participant.

Weeks 1-8
Medication Adherence Measured by the 8-Item Morisky Medication Adherence Scale (MMAS-8)
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Total score ranges from 0 to 8; higher scores indicate better adherence.

Baseline (week 0), week 8, and 6 months after week 8
Number of Participants Reporting Current Tobacco Use, Assessed by Self-Report Questionnaire
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Participants reporting any tobacco use in the past 30 days

Baseline (week 0), week 8, and 6 months after week 8
Muscle Mass Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)
Časové okno: Baseline (week 0) and week 8

Muscle mass in kilograms.

Baseline (week 0) and week 8
Body Fat Percentage Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)
Časové okno: Baseline (week 0) and week 8

Body fat as a percentage of body weight.

Baseline (week 0) and week 8
Forced Vital Capacity (FVC) Measured by Spirometry
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

FVC in liters.

Baseline (week 0), week 8, and 6 months after week 8
Forced Expiratory Volume in 1 Second (FEV1) Measured by Spirometry
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

FEV1 in liters.

Baseline (week 0), week 8, and 6 months after week 8
Ratio of FEV1 to FVC (FEV1/FVC) Measured by Spirometry
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

FEV1/FVC expressed as a percentage.

Baseline (week 0), week 8, and 6 months after week 8
Minute Ventilation to Carbon Dioxide Output Slope (VE/VCO2 Slope) Measured by Cardiopulmonary Exercise Testing
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Slope of the linear relationship between minute ventilation and carbon dioxide output during exercise (unitless); lower values indicate better ventilatory efficiency.

Baseline (week 0), week 8, and 6 months after week 8
Oxygen Uptake Efficiency Slope (OUES) Measured by Cardiopulmonary Exercise Testing
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Slope of oxygen uptake (mL/min) against the log10 of minute ventilation (L/min); higher values indicate better efficiency.

Baseline (week 0), week 8, and 6 months after week 8
Oxygen Uptake at the First Ventilatory Threshold (VO2 at VT1) Measured by Cardiopulmonary Exercise Testing
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

VO2 at the first ventilatory threshold in mL/kg/min.

Baseline (week 0), week 8, and 6 months after week 8
Heart Rate Recovery at 1 Minute (HRR1) After Cardiopulmonary Exercise Testing
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Peak heart rate minus heart rate 1 minute into recovery, in beats per minute; higher values indicate better recovery.

Baseline (week 0), week 8, and 6 months after week 8
Heart Disease-Specific Quality of Life Measured by the MacNew Heart Disease Health-Related Quality of Life Questionnaire Global Score
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

27 items; global score ranges from 1 to 7; higher scores indicate better health-related quality of life.

Baseline (week 0), week 8, and 6 months after week 8
Depressive Symptoms Measured by the Patient Health Questionnaire-9 (PHQ-9) Total Score
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Total score ranges from 0 to 27; higher scores indicate more severe depressive symptoms.

Baseline (week 0), week 8, and 6 months after week 8
Anxiety Symptoms Measured by the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
Časové okno: Baseline (week 0), week 8, and 6 months after week 8

Total score ranges from 0 to 21; higher scores indicate more severe anxiety symptoms.

Baseline (week 0), week 8, and 6 months after week 8
Number of Participants With Adverse Events During Exercise Testing, Supervised Training or Home Exercise
Časové okno: From baseline (week 0) through 6 months after week 8 (approximately 8 months)

Adverse events include cardiovascular events (e.g., arrhythmia requiring intervention, angina, syncope, abnormal blood pressure response, myocardial infarction, stroke, death), musculoskeletal injury and sternal wound complications, recorded by therapists, the remote ECG review, the exercise log and weekly telephone calls.

From baseline (week 0) through 6 months after week 8 (approximately 8 months)
Number of Participants Who Discontinue the Intervention
Časové okno: Weeks 1-8

Participants who stop the assigned intervention for any reason; reasons are reported.

Weeks 1-8

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Yu-Shan Lin, PT, MSc, CRFC, Chief Physical Therapist, Cheng Hsin General Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

28. února 2028

Dokončení studie (Odhadovaný)

31. července 2028

Termíny zápisu do studia

První předloženo

3. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • CHGH115-114-18

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .